Strategic Collaborations Leverage Anixa’s established collaborations with Moffitt Cancer Center and Cleveland Clinic to position complementary services or technologies that align with their CER-T ovarian immunotherapy and cancer vaccine programs, offering partnerships that can accelerate clinical development or expand platform applications.

Clinical-stage Opportunities Target outreach around Anixa’s ongoing Phase 1 trials for lira-cel and breast/ovarian cancer vaccine programs to explore co-development, licensing, or translational research collaborations that can enhance trial outcomes or broaden indication coverage.

Vaccine Platform Fit Present vaccine platform capabilities to support their immunotherapy and vaccine programs, including combination strategies, adjuvant optimization, or proteomics-informed diagnostics that could improve patient selection and response monitoring.

Diagnostics Synergy Explore proteomics-based diagnostic technology opportunities referenced in recent news to offer companion diagnostics or patient stratification tools that increase trial efficiency, regulatory readiness, and market adoption.

Funding and Visibility Position services around accelerating clinical milestones and regulatory submissions to align with Anixa’s growth trajectory, including investor-focused data packages, clinical trial analytics, and strategic advisory to support funding rounds.